发明授权
US08961957B2 Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10
有权
肿瘤内引入具有抗TNF和/或抗IL-10的细胞毒性T淋巴细胞和/或NKT细胞的治疗和方法
- 专利标题: Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10
- 专利标题(中): 肿瘤内引入具有抗TNF和/或抗IL-10的细胞毒性T淋巴细胞和/或NKT细胞的治疗和方法
-
申请号: US13928844申请日: 2013-06-27
-
公开(公告)号: US08961957B2公开(公告)日: 2015-02-24
- 发明人: Kenichiro Hasumi
- 申请人: Hasumi International Research Foundation
- 申请人地址: US DC Washington
- 专利权人: Hasumi International Research Foundation
- 当前专利权人: Hasumi International Research Foundation
- 当前专利权人地址: US DC Washington
- 代理机构: Eckert Seamans Cherin & Mellott, LLC
- 代理商 Carol A. Marmo
- 主分类号: A01N63/00
- IPC分类号: A01N63/00 ; A61K45/00 ; A61K47/00 ; A61K39/395 ; C12N5/0786 ; C12N5/0783 ; C07K16/24
摘要:
The invention relates to therapy and methods of applying the therapy to cancer patients. The invention includes introducing intratumorally cytotoxic T lymphocyte and/or NKT cells, and prior to, coincident with, or following introducing intratumorally the cytotoxic T lymphocyte and/or NKT cells, introducing intratumorally anti-TNF and/or anti-IL-10 to the patient. The cytotoxic T lymphocyte and/or NKT cells can be induced by the intratumoral introduction of immature dendritic cells to the patient. This therapy of the invention can be effective to regress, reduce or eliminate tumor cells in tumor tissue of the patients in the absence of radiation therapy.
公开/授权文献
信息查询